Asterand Bioscience has almost 20 years’ experience of performing human tissue-based IHC, with a specialty in custom assay development for commercially-available or client-generated antibodies and binding molecules (biosimilars, bi-specifics and antibody-drug conjugates). Our scientists apply rigorous approaches to deliver intelligent assay design, optimized and robust immunostaining protocols, and expert data interpretation. IHC assays are fully automated and run on Dako Autostainer Plus, Ventana Discovery XT or Leica BondRx machines.
Our comprehensive expertise allows us to offer our 7-step antibody validation.
With an extensive tissue bank, we specifically customize your project to your needs. Asterand Bioscience has working protocols for targeting a wide range of oncology targets, plus routine immune cell markers. Asterand Bioscience recently adopted the PerkinElmer Vectra® Polaris™ Automated Quantitative Pathology Imaging System to extend their services capabilities to drug and diagnostic development scientists working in the Immuno-Oncology (IO) field. Capitalizing on over 20 years of expertise in human tissue-based research, Asterand Bio scientists are excited extend this additional solution platform to their clients.
With the increasing demands for experimental validation of therapeutic antibodies and antibody-like molecules, Asterand Bioscience has developed protocols for the validation. We are able to detect a wide range of potentially clinically relevant molecules and can confirm the specificity of their binding.
Asterand Bioscience applies 20 years of experience in immunohistochemical studies to provide Tissue Cross Reactivity (TCR) services to Good Laboratory Practice (GLP). Our team ensures that a tailored scientific approach results in the delivery of high quality data within defined timelines.
Asterand Bioscience understands the importance of immuohistochemistry to the drug discovery and companion diagnostic researchers. Our scientists work in a GLP-accredited laboratory following established protocols and utilizing multiple established IHC platforms. With multiple detection and analysis platforms at hand, Asterand Bio is able to optimize and validate IHC protocols to specific requirements and needs.